Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain

  1. Martín García-Sancho, A.
  2. Presa, M.
  3. Pardo, C.
  4. Martín-Escudero, V.
  5. Oyagüez, I.
  6. Ortiz-Maldonado, V.
Revue:
Cancers

ISSN: 2072-6694

Année de publication: 2024

Volumen: 16

Número: 13

Type: Article

DOI: 10.3390/CANCERS16132301 GOOGLE SCHOLAR lock_openAccès ouvert editor